Resource Summary Report

Generated by NIF on Sep 17, 2026

LA-N-5

RRID:CVCL_0389
Type: Cell Line

Proper Citation

RRID:CVCL_0389

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0389

Proper Citation: RRID:CVCL_0389

Description: Cell line LA-N-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: PMID:6172518, PMID:15892104, PMID:18082704, PMID:18724359, PMID:18923524, PMID:20164919, PMID:20655465, PMID:22213050, PMID:23202128, PMID:24466371, PMID:24792489, PMID:28350380

Comments: Miscellaneous: On the basis that LA-350 (Cellosaurus=CVCL_AR50) and LA-N-5 are both established by Seeger R.C., that they share identical STR profiles and that LA-350 is said to originate from a patient suffering from neuroblastoma we have annotated them as being autologous cell lines.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LA-N-5

Synonyms: LAN-5, Lan-5, LAN5, Lan5, NBLAN5T

Cross References: BTO:BTO_0000935, CLO:CLO_0007242, CLO:CLO_0050264, EFO:EFO_0022688, MCCL:MCC:0000284, CLDB:cl3170, CLDB:cl3171, ArrayExpress:E-MTAB-783, BioSample:SAMN03472329, BioSample:SAMN03473428, cancercelllines:CVCL_0389, Cosmic:801742, Cosmic:920242, Cosmic:923828, Cosmic:930066, Cosmic:947705, Cosmic:1037345, Cosmic:1099142, Cosmic:1109122, Cosmic:1153783, Cosmic:1161992, Cosmic:1167989, Cosmic:1212538, Cosmic:1518068,

Cosmic:1526629, Cosmic:1890201, Cosmic:2131580, Cosmic:2239462, Cosmic:2301576, Cosmic:2393636, DSMZ:ACC-673, DSMZCellDive:ACC-673, GEO:GSM313804, GEO:GSM333799, GEO:GSM692871, GEO:GSM2371239, GEO:GSM2394369, GEO:GSM4104579, GEO:GSM4104580, GEO:GSM4104628, GEO:GSM4104629, GEO:GSM4105313, GEO:GSM4105314, GEO:GSM4105315, GEO:GSM4105316, GEO:GSM4105317, IARC_TP53:21459, ICLC:HTL96022, LINCS_LDP:LCL-1987, Lonza:1157, NCBI_Iran:C613, Progenetix:CVCL_0389, RCB:RCB0485, Wikidata:Q54901878

ID: CVCL_0389

Record Creation Time: 20220427T220716+0000

Record Last Update: 20260913T004719+0000

Ratings and Alerts

No rating or validation information has been found for LA-N-5.

Warning: Discontinued: ICLC; HTL96022
Miscellaneous: On the basis that LA-350 (Cellosaurus=CVCL_AR50) and LA-N-5 are both established by Seeger R.C., that they share identical STR profiles and that LA-350 is said to originate from a patient suffering from neuroblastoma we have annotated them as being autologous cell lines.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Bajgain P, et al. (2026) Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell reports. Medicine, 7(5), 102782.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications, 5(1), 167.

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. Cancer research communications, 4(3), 723.

Pucci P, et al. (2024) Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. Nature communications, 15(1), 3422.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. Molecular oncology.

Lee JY, et al. (2023) Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell reports. Medicine, 4(6), 101091.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Rösch L, et al. (2023) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. Molecular oncology, 17(1), 37.

Shulman D, et al. (2023) Sex-specific declines in cholinergic-targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease. bioRxiv : the preprint server for biology.

Heitzeneder S, et al. (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer cell, 40(1), 53.

Tao L, et al. (2022) MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nature communications, 13(1), 3728.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. Molecular cancer therapeutics, 20(11), 2228.

O'Donohue TJ, et al. (2021) Translational Strategies for Repotrectinib in Neuroblastoma. Molecular cancer therapeutics, 20(11), 2189.

Böckelmann LC, et al. (2021) YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. Cellular oncology (Dordrecht), 44(5), 1183.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Wertman JN, et al. (2020) The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model. eLife, 9.

Vrenken KS, et al. (2020) The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy. Biochimica et biophysica acta. Molecular basis of disease, 1866(3), 165644.

Ghandi M, et al. (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 569(7757), 503.